MedTrace Logo

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

NCT07610369 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-28

No results posted yet for this study

Summary

The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

Conditions

Interventions

DRUG

Psilocybin (drug)

Single dose of psilocybin ranging from low ("microdose") to high delivered orally with psychological support and monitoring

DRUG

Psilocybin (drug)

Single dose of psilocybin ranging from low ("microdose") to high delivered orally with psychological support and monitoring

Sponsors & Collaborators

  • Michael J. Fox Foundation for Parkinson's Research

    collaborator OTHER

  • Yale University

    lead OTHER

Principal Investigators

  • Sophie Holmes, PhD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2030-05-31
Completion
2030-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07610369 on ClinicalTrials.gov